Table 2.
Molecular characteristics among women with a primary DCIS who later developed either an invasive cancer or an in situ recurrence. Women with a known recurrence were recruited from two source populations: a population based cohort (U/V cohort, n = 458) and a randomized study (SweDCIS, n = 1,046).
| Molecular Characteristics of primary DCIS |
All DCIS with a recurrence (n = 266) | |||||
|---|---|---|---|---|---|---|
|
U/V cohort (n = 100) Type of recurrence |
SweDCIS (n = 166) Type of recurrence |
All DCIS with a recurrence (n = 266) Type of recurrence |
||||
| Invasive (n = 55) Number |
In situ (n = 45) Number |
Invasive (n = 81) Number |
In situ (n = 85) Number |
Invasive (n = 136) Number (%) |
In situ (n = 130) Number (%) |
|
| ER (n = 181) | ||||||
| Positive | 38 | 27 | 36 | 32 | 74 (81.3) | 59 (65.5) |
| Negative | 10 | 16 | 7 | 15 | 17 (18.7) | 31 (34.5) |
| PR (n = 183) | ||||||
| Positive | 25 | 20 | 28 | 24 | 53 (55.8) | 44 (50.0) |
| Negative | 26 | 22 | 16 | 22 | 42 (44.2) | 44 (50.0) |
| HER2 (n = 177) | ||||||
| Positive | 15 | 18 | 13 | 22 | 28 (30.4) | 40 (47.1) |
| Negative | 37 | 24 | 27 | 21 | 64 (69.6) | 45 (52.9) |
| EGFR (n = 143) | ||||||
| Positive | 10 | 16 | 14 | 19 | 24 (32.0) | 35 (51.5) |
| Negative | 33 | 18 | 18 | 15 | 51 (68.0) | 33 (48.5) |
| CK5/6 (n = 170) | ||||||
| Positive | 42 | 32 | 40 | 46 | 82 (94.3) | 78 (94.0) |
| Negative | 3 | 4 | 2 | 1 | 5 (5.7) | 5 (6.0) |
| KI67 (n = 146) | ||||||
| High | 15 | 11 | 13 | 16 | 28 (37.3) | 27 (38.0) |
| Low | 32 | 25 | 15 | 19 | 47 (62.7) | 44 (62.0) |
| Subgroups based on IHC (n = 266) | ||||||
| ER+/HER2− | 10 | 6 | 8 | 9 | 51 (37.5) | 36 (28.0) |
| ER+/HER2+ | 28 | 19 | 23 | 17 | 18 (13.2) | 15 (11.5) |
| ER−/HER2+ | 4 | 11 | 4 | 10 | 8 (5.9) | 21 (16.2) |
| **ER−/HER2−/CK+ or EFGR+ | 3 | 5 | 3 | 3 | 6 (4.4) | 8 (6.2) |
| Unknown | 10 | 4 | 43 | 46 | 53 (39.0) | 58 (44.6) |